

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application Number	08/444,790
	Filing Date	May 19, 1995
	First Named Inventor	Brockhaus
	Art Unit	1646
	Examiner Name	Zachary C. Howard
	Attorney Docket Number	01017/40451B

**U.S. PATENTS**

Examiner Initial	Cite No	Patent Number	Kind Code	Issue Date	Name of Patentee or Applicant of cited Document
	A1				
	A2				

**U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initial	Cite No	Publication Number	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document
	B1				
	B2				

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Cite No	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	English Translation attached YES NO
	C1						
	C2						
	C3						
	C4						
	C5						

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.
	D1	ARORA et al., "Differences in Binding and Effector Functions Between Classes of TNF Antagonists," Cytokine 45: 124-131 (2009)
	D2	FURST et al., "Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection," Semin. Arthritis Rheum. 36: 159-167 (2006)
	D3	MITOMA et al., "Mechanisms for Cytotoxic Effects of Anti-Tumor Necrosis Factor Agents on Transmembrane Tumor Necrosis Factor $\alpha$ -Expressing Cells," Arthr. & Rheum. 58(5): 1248-1257 (2008)
	D4	STRANGFELD et al., "Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Anti-TNF- $\alpha$ Agents," JAMA 301(7): 737-744 (2009)

Examiner Signature: /Zachary Howard/	Date Considered: 07/21/2011
EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	08/444,790
			Filing Date	May 19, 1995
			First Named Inventor	Brockhaus
			Art Unit	1646
			Examiner Name	Zachary C. Howard
			Attorney Docket Number	01017/40451B
	D5	WALLIS et al., "Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists," Clin. Inf. Dis. 38: 1261-1265 (2004)		
	D6	WALLIS et al., "Reactivation of Latent Granulomatous Infections by Infliximab," Clin. Inf. Dis. 41(Suppl 2): S1-S5 (2005)		
	D7	WINZOR et al., "Evaluation of Equilibrium Constants from Precipitin Curves: Interaction of $\alpha$ -Crystallin with an Elicited Monoclonal Antibody," Arch. Biochem. Biophys. 268(1): 221-226 (1989)		
	D8	AVIS, Kenneth, Parental Preparations, Remington Pharmaceutical Sciences, Chapter 85, pages 1518-1541 (1985).		
	D9	Center for Drug Evaluation and Research, Guidelines on Sterile Drug Products Produced by Aseptic Processing, Published by the FDA June 1987.		

Examiner Signature:	/Zachary Howard/	Date Considered:	07/21/2011
EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.H./